By Juliette Goodrich & Molly McCrea
SAN FRANCISCO (CBS SF) Imagine being told you have just a few years left to live and a promising cutting-edge treatment exists that could extend your life, but no amount of money can buy it.
This scenario is not the plot of Hollywood movie. It is happening to several individuals who find themselves in this unfortunate predicament.
KPIX 5 was recently contacted by a woman who lives here in the Bay Area who is facing this dilemma.
Gwen Peterson moved to San Francisco 8 years ago from New England to begin a new job. Within weeks, she met the love of her life.
They say we met the old-fashioned way in a bar! said Gwen, smiling.
Her husband Nate broke into laughter, nodding his head.
Gwen and Nate married in 2017. The young couple was looking forward to starting a family. But before they could celebrate their first wedding anniversary, Gwen started experiencing some unusual symptoms.
My left foot was dragging and scuffing on the ground which led to dozens of falls, trips to the ER, noted Gwen.
Gwen would end up diagnosed with a progressive neurological disease called amyotrophic lateral sclerosis or ALS for short. Its commonly called Lou Gehrigs Disease.
ALS is 100% fatal unfortunately. Patients usually live 2 to 5 years after their first symptom, said UCSF neurologist Dr. Catherine Lomen-Hoerth, who specializes in treating patients with ALS and is Gwens physician.
ALS is a motor neuron disorder. It attacks nerve cells in the brain and spinal cord. It progressively robs people of their ability to move, speak, and ultimately breathe.
The first thought is Well, what do we do about this? Whats our action? How do we get treatment for this?, recollected Nate.
Nate and Gwen then heard how the treatment includes only 2 FDA approved drugs that show modest benefit.
Its hard so being 32 years old, diagnosed with a disease thats still a death sentence and not want to fight. I immediately wanted to start fighting, remembered Gwen.
The clock was ticking. Gwen had to choose between getting pregnant or joining a clinical trial. If they qualify for a trial, ALS patients only have time to participate in one trial. When they progress too far, these trials are commonly out of reach for them.
It was an extremely difficult decision, said Gwen.
She picked the trial and enrolled in a study that uses mesenchymal stem cells, harvested from the bone marrow taken from a hip bone in her body.
Mesenchymal stem cells are multipotent adult stem cells
These cells are cultured in a lab to produce a substance that may help nerves stay healthy. The experimental therapy is called NurOwn. Its developed by a biotech company called BrainStorm. The therapy is a biologic which in Gwens case was delivered via lumbar puncture.
The hope is that the therapy would slow or prevent the progression of the disease. Gwen had a 50-50 chance of getting the actual unproven therapy. She may have also gotten a placebo. But she is certain she got the real thing.
Gwen told KPIX 5 that it worked for her.
I have no doubt that I have stabilized, said Gwen.
Dr. Lomen-Hoerth was not involved in the study and told KPIX 5 that the trial has not yet made public who got the real agent and who got placebo. But she said without a doubt, her patients really need better treatments. She would also like patients to gain more access to promising unproven therapies.
Itd be fantastic if patients could have more access to these drugs because the requirement s in order to enroll in a clinical trial are very strict, said the UCSF neurologist.
The trial ended. But the FDA stated the results do not help a majority of patients.
Those running the trial believe there was a benefit for a smaller group of those enrolled. The therapy remains unapproved.
At the end of the trial, Gwen was eligible to receive only 3 more doses of the experimental therapy. Her last treatment was in July. Now it is out of her reach.
When an individual has this death sentence, I believe they should have access to drug that shows promise, said Representative Anna Eshoo, who represents Californias 18th Congressional District that includes parts of Santa Clara, San Mateo, and Santa Cruz counties.
On July 29th, the Congresswoman recently chaired a subcommittee hearing on neurodegenerative diseases. Her office was contacted by another ALS patient named Jamie Berry from the South Bay.
People often say to me, you dont seem to have ALS because it hasnt affected my speech or my breathing yet. but you know Im in a wheelchair I cant walk, and my right hand is crippled, Jamie told KPIX 5.
Jamie Berry explains how people can help:
The panel heard from patients urging lawmakers to ensure the FDA act with greater speed and flexibility
They also want companies to make it easier for patients to gain access more quickly to promising unapproved therapies.
When you are suffering and every single day your body is dying, then I think patients deserve dosages of hope, Congresswoman Eshoo told KPIX 5.
50 million Americans are affected by neurological disorders such as ALS, Alzheimers Disease, Huntingtons Disease, and Parkinsons Disease.
Eshoo told the panel how treatments for these conditions take on average 50% longer to reach approval. But these patients dont have that kind of time.
We have more treatments in the pipeline than ever. However, we need access, said Gwen.
Every day I see the challenges of this disease and I know its going to get worse It is frightening. And so, anything I can do to help keep her with me and be my best friend is worth fighting for, added Nate.
One way theyre fighting: these patients and their families have joined I am ALS. The group was created by patients for patients. Members are seeking to accelerate the development of drugs and also to make promising therapies more quickly accessible.
There are two bills now in front of lawmakers and theyve received bipartisan support. But during the pandemic, these laws may get lost in the shuffle.
These patients are urging everyone to take a moment and contact their federal representatives and urge them to act before October. If not, the bills may get passed to the next session, and these patients dont have that kind of time.
Jamie Berry has created a web link to make it easy for KPIX viewers to contact their representative.
More info on ALS:
ALS.org website
Brainstorm Pharma
Video excerpt of subcommittee hearing on neurodegenerative diseases
I am ALS,org
Overview of Act For ALS bills
Read this article:
A Dosage Of Hope: ALS Patients Fight For a Chance At Promising Therapies - CBS San Francisco
- Adult Stem Cells: What They Are and What They Do - February 6th, 2025
- What Are Adult Stem Cells and Are They Right for You? - February 6th, 2025
- Stem Cell Program | Adult Stem Cells - Boston Children's Hospital - February 6th, 2025
- Different Types Of Stem Cells: Embryonic Vs. Adult ... - January 17th, 2025
- Rejuvenation of Aging Adult Stem Cells to Improve their Regenerative Potential - Frontiers - January 13th, 2025
- Hope Biosciences Research Foundation Authorized to Begin Phase II Clinical Trial in Stem Cell Therapy for Juvenile Idiopathic Arthritis - Business... - December 22nd, 2024
- What Are Stem Cells? Biomedical Beat Blog National Institute of ... - November 29th, 2024
- TVHS opens stem cell processing lab to expand biotherapies | VA Tennessee Valley health care | Veterans Affairs - Veterans Affairs - November 8th, 2024
- Understanding Mature Tissue or Organ Stem Cells and Their Clinical ... - November 8th, 2024
- Biology of stem cells: an overview - PMC - PubMed Central (PMC) - October 30th, 2024
- New government tech deals boost the business of cancer detection - GOV.UK - October 11th, 2024
- Stem cell therapy reverses type 1 diabetes in world first - Yahoo News UK - October 11th, 2024
- Advances in different adult stem cell-derived exosomal non-coding RNAs for the treatment of neurological disorders: a narrative review - Frontiers - September 26th, 2024
- Breakthrough technique may help speed understanding, treatment of MD, ALS - Harvard Gazette - September 14th, 2024
- Rostock University Explores Use of Stem Cells for Meat Cultivation with Help from Innocent Meat - vegconomist - the vegan business magazine - August 12th, 2024
- Entero Therapeutics’ Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program - July 31st, 2024
- Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024 - July 31st, 2024
- Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update - July 31st, 2024
- Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024 - July 31st, 2024
- Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024 - July 31st, 2024
- Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7 - July 31st, 2024
- Paratek Pharmaceuticals Completes Five-Year Microbiologic Surveillance Study of NUZYRA® (omadacycline) Demonstrating No Change in In Vitro Potency... - July 31st, 2024
- Targeting the stem cell niche micro-environment as therapeutic strategies in aging - Frontiers - June 28th, 2024
- International trial introduces another curative option for sickle cell disease - EurekAlert - June 28th, 2024
- HOX genes in stem cells: Maintaining cellular identity and regulation of differentiation - Frontiers - June 28th, 2024
- Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference - June 21st, 2024
- Intelligent Bio Solutions Broadens UK Customer Base by Securing Two Key Accounts with Over 70 Locations and Over 15,000 Employees in the Warehouse and... - June 21st, 2024
- Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management - June 21st, 2024
- Scilex Holding Company Partners with New National Distributor, Endeavor Distribution LLC. - June 21st, 2024
- Firefly Neuroscience, an AI-Driven Brain Health Company, Appoints Samer Kaba, MD as Chief Medical Officer - June 21st, 2024
- API and the University of Alberta Break Ground in Edmonton on Canada’s Largest Manufacturing Facility for Critical Medicines - June 21st, 2024
- Syntekabio Signs Memorandum of Understanding with bioSeedin/ACROBiosystems - June 21st, 2024
- Rapafusyn Pharmaceuticals Secures $28 Million Series A to Advance Its Non-Degrading Molecular Glue Drug Discovery Platform - June 21st, 2024
- Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog... - June 21st, 2024
- Rakovina Therapeutics Announces Oversubscribed Private Placement and Results from 2024 Annual General Meeting - June 21st, 2024
- Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing - June 21st, 2024
- NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference - June 21st, 2024
- Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran - June 21st, 2024
- Idorsia’s novel treatment for chronic insomnia wins the prestigious Prix Galien Suisse 2024 innovation award in the ‘Primary & Speciality’... - June 21st, 2024
- Radiopharm Receives Strategic Investment for up to A$18 million - June 21st, 2024
- Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee - June 21st, 2024
- Trading by management and close relations of management - June 21st, 2024
- Major shareholder announcement - June 21st, 2024
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - June 21st, 2024
- Nature retracts highly cited 2002 paper that claimed adult stem cells could become any type of cell - Retraction Watch - June 19th, 2024
- Shares of Biotech MicroCap Rip on Licensing Talks - The Globe and Mail - June 15th, 2024
- Syntekabio to Showcase Advanced AI Drug Discovery Technologies at BIO International Convention 2024 - May 23rd, 2024
- Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 23rd, 2024
- Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist... - May 23rd, 2024
- Hornet Therapeutics emerges from stealth with data published in Science demonstrating the first potential drug intervention for Epstein-Barr Virus... - May 23rd, 2024
- Oxurion Announces Results on the Annual Shareholders’ Meeting of 16 May 2024 - May 23rd, 2024
- New York Blood Center Enterprises Celebrates the Expansion of Cell & Gene Therapy GMP Manufacturing Capabilities at the Grand Opening of... - May 23rd, 2024
- Syneos Health Leaders Recognized as PM360 ELITE 100 Award Recipients - May 23rd, 2024
- Kane Biotech Announces First Quarter 2024 Financial Results - May 23rd, 2024
- Beyond Air® Schedules Fiscal Year End 2024 Financial Results Conference Call and Webcast - May 23rd, 2024
- Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy - May 23rd, 2024
- Harvard Bioscience, Inc. to Present at the Jefferies Global Healthcare Conference on June 5, 2024 - May 23rd, 2024
- 23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results - May 23rd, 2024
- Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting - May 23rd, 2024
- Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting - May 23rd, 2024
- Tizona Therapeutics Presents Phase 1b TTX-080 Clinical Data in Advanced Colorectal Cancer and Head and Neck Squamous Cell Carcinoma at ASCO 2024 - May 23rd, 2024
- Inotiv, Inc. to Participate in Upcoming Craig Hallum and Jefferies Investor Conferences - May 23rd, 2024
- NANOBIOTIX to Present at the Jefferies Global Healthcare Conference - May 23rd, 2024
- Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - May 23rd, 2024
- Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual... - May 23rd, 2024
- Biology of stem cells: an overview - PMC - National Center for ... - March 26th, 2024
- Iron Limitation Preserves Youthfulness of Blood Stem Cells - Mirage News - March 13th, 2024
- Mini organs grown from stem cells of unborn babies for the first time in breakthrough - The Mirror - March 9th, 2024
- The Effect of Short-Term NAD3 Supplementation on Circulating Adult Stem Cells in Healthy Individuals Aged 40-70 ... - Cureus - March 7th, 2024
- University of Liverpool Spin-Out Emerges, Pioneering Novel Adult Stem Cell-Based Therapies - India Education Diary - March 7th, 2024
- Scientists have used cells from fluid drawn during pregnancy to grow mini lungs and other organs - Yahoo News Canada - March 6th, 2024
- Japan approves new stem cell-based Alzheimer's therapy By Proactive Investors - Investing.com Australia - January 20th, 2024
- Cyberstalking pits Harvard professor against PubPeer Retraction ... - Retraction Watch - December 5th, 2023
- 10 functional health predictions for 2024, according to a doctor and ... - 1330 WFIN - December 5th, 2023
- See the Brain Like Never Before in This Gorgeous Art - Scientific American - December 5th, 2023
- Geron Announces Publication in The Lancet of Results from the ... - BioSpace - December 5th, 2023
- Stem cell injections could be the key to curing MS - Freethink - December 3rd, 2023
- Jaypirca (pirtobrutinib) Now Approved by U.S. FDA for the ... - Investors | Eli Lilly and Company - December 3rd, 2023
- Comparative Efficacy and Safety of Four JAK Inhibitors for ... - HealthDay - December 3rd, 2023
- City lights up for Francis on Anthony Nolan's birthday - Liverpool Express - December 3rd, 2023
Recent Comments